Tele-monitoring of Post Join Arthroplasty Outcomes: A Feasibility Study

August 15, 2023 updated by: Sameer Naranje, University of Alabama at Birmingham
The purpose of this study is to develop an effective telephone mediated follow-up system to reduce the number of unplanned readmissions and emergency department visits after total joint arthroplasty. This will help reduce costs related to unnecessary visits to the hospital as well as catch complications earlier on. The investigators plan to accomplish this by performing a pilot study that will compare the outcomes of using an Interactive Voice Response system through phone call in addition to the standard follow-up protocol. The outcomes of this group will be compared to those receiving the standard of care follow-up protocol.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Upon patient education and consent to participate in this study, patients will be randomized via online randomizer during their baseline visit into either Treatment As Usual (TAU) or Integrated Voice Response (IVR) cohorts. During this baseline visit, the patients in the IVR group will be given specific information on the nature of the calls and what to expect. Both groups will fill out a form for assessing their baseline pain and functionality. Both groups will receive standard total joint arthroplasty. After this, the TAU group will receive the standard of care which involves appropriate pain management and scheduled clinic follow-ups lasting approximately 60 minutes at 2 weeks, 6 weeks, and 12 weeks along with additional visits if required. Clinic visits will assess pain via VAS scale, joint functionality via HOOS and KOOS scale, and quality of life via SF-36.

In addition to the standard of care follow-up visits as in the TAU group, the IVR group will also receive automated phone calls lasting up to 3 minutes, which will be the focus of this research study. These phone calls will be daily for the first week, every other day the second week, twice a week for weeks 3-6, and weekly for weeks 7-12. The content of these calls will assess pain management, wound healing and screen for potential complications through a series of questions (questionnaire script attached). At the completion of each call, the patient will be instructed to either continue standard treatment or visit the emergency department based on the content of their response. If there is reason for concern, the PI will automatically be informed.

Survey questions pertaining to the patients outcomes and satisfaction will be completed in clinic and collected by the PI. The responses and data relating to IVR calls will made available through computer software designed by our team on the secure REDcap network.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35205
        • UAB Highland Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants eligible to undergo the TJA surgical procedure

Exclusion Criteria:

  • Participants who are not eligible to undergo the TJA surgical procedure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Telemedicine Group
Group that will be receiving the telemedicine intervention in addition to the standard of care post-op.
IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
Other Names:
  • Integrated Voice Response (IVR)
No Intervention: Standard Treatment
Patients will be receiving the standard of care, post op visits at 2, 6, and 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Patients with acceptable pain control as measured by Visual Analogue scale
Time Frame: 2 week
VAS is a patient measured scale to evaluate pain, on a scale of 1-10 with 10 being the worst pain.
2 week
Percentage of Patients with acceptable pain control as measured by Visual Analogue scale
Time Frame: 6 weeks
VAS is a patient measured scale to evaluate pain, on a scale of 1-10 with 10 being the worst pain.
6 weeks
Percentage of Patients with acceptable pain control as measured by Visual Analogue scale
Time Frame: 12 weeks
VAS is a patient measured scale to evaluate pain, on a scale of 1-10 with 10 being the worst pain.
12 weeks
Percentage of Patients with acceptable pain control as measured by Visual Analogue scale
Time Frame: Baseline
VAS is a patient measured scale to evaluate pain, on a scale of 1-10 with 10 being the worst pain.
Baseline
Percentage of Patients with acceptable joint functionality as measured by hip disability and osteoarthritis outcome score (HOOS)
Time Frame: Baseline
HOOS is patient measured scores evaluating Hip function and creates a score out of 100, 100 indicating full functionality.
Baseline
Percentage of Patients with acceptable joint functionality as measured by hip disability and osteoarthritis outcome score (HOOS) and knee disability and osteoarthritis outcome score (KOOS)
Time Frame: Baseline
KOOS is a patient measured score evaluating Hip function and creates a score out of 100, 100 indicating full functionality.
Baseline
Percentage of Patients with acceptable joint functionality as measured by knee disability and osteoarthritis outcome score (KOOS)
Time Frame: 2 weeks
KOOS is a patient measured score evaluating knee function and creates a score out of 100, 100 indicating full functionality.
2 weeks
Percentage of Patients with acceptable joint functionality as measured by hip disability and osteoarthritis outcome score (HOOS)
Time Frame: 2 weeks
HOOS is a patient measured score evaluating knee function and creates a score out of 100, 100 indicating full functionality.
2 weeks
Percentage of Patients with acceptable joint functionality as measured by hip disability and osteoarthritis outcome score (HOOS)
Time Frame: 6 weeks
HOOS is a patient measured score evaluating Hip function and creates a score out of 100, 100 indicating full functionality.
6 weeks
Percentage of Patients with acceptable joint functionality as measured by knee disability and osteoarthritis outcome score (KOOS)
Time Frame: 6 weeks
KOOS is a patient measured score evaluating knee function and creates a score out of 100, 100 indicating full functionality.
6 weeks
Percentage of Patients with acceptable joint functionality as measured by hip disability and osteoarthritis outcome score (HOOS)
Time Frame: 12 weeks
HOOS is a patient measured scores evaluating Hip function and creates a score out of 100, 100 indicating full functionality.
12 weeks
Percentage of Patients with acceptable joint functionality as measured by knee disability and osteoarthritis outcome score (KOOS)
Time Frame: 12 weeks
KOOS is a patient measured score evaluating Hip and knee function and creates a score out of 100, 100 indicating full functionality.
12 weeks
Percentage of Patients with acceptable quality of life as measured by Short Form Health Survey SF-36
Time Frame: Baseline
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
Baseline
Percentage of Patients with acceptable quality of life as measured by Short Form Health Survey SF-36
Time Frame: 2 weeks
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
2 weeks
Percentage of Patients with acceptable quality of life as measured by Short Form Health Survey SF-36
Time Frame: 6 weeks
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
6 weeks
Percentage of Patients with acceptable quality of life as measured by Short Form Health Survey SF-36
Time Frame: 12 weeks
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sameer Naranje, MD, Assistant Professor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 16, 2021

Primary Completion (Actual)

August 15, 2023

Study Completion (Actual)

August 16, 2023

Study Registration Dates

First Submitted

October 6, 2020

First Submitted That Met QC Criteria

October 13, 2020

First Posted (Actual)

October 14, 2020

Study Record Updates

Last Update Posted (Actual)

August 16, 2023

Last Update Submitted That Met QC Criteria

August 15, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-300005894

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post-Op Complication

Clinical Trials on Telemedicine

Subscribe